Blue Lake Biotechnology’s Intranasal COVID-19 Vaccine Candidate Demonstrates Long-Lasting Immunity and Broad Protection Blue Lake Biotechnology, Inc., a clinical-stage biotechnology company specializing in intranasal vaccine development, along with its affiliate…
Health Canada Approves 4Moving Biotech’s Phase 2a Trial for Knee Osteoarthritis 4Moving Biotech (4MB), a spin-off of 4P-Pharma dedicated to developing first-in-class treatments that modify the natural history of knee…
Alcon Acquires Majority Stake in Aurion Biotech to Advance Corneal Cell Therapy Alcon, a global leader in eye care, has announced the acquisition of a majority interest in Aurion Biotech,…
Savara Secures Up to $200 Million in Non-Dilutive Debt Financing from Hercules Capital Savara Inc., a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for rare respiratory diseases, has announced…
FDA Approves CABOMETYX® (Cabozantinib) for Advanced Neuroendocrine Tumors, Expanding Treatment Options Exelixis, Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved CABOMETYX® (cabozantinib) for the treatment…
Viz.ai AI-Powered Solution Identifies Hypertrophic Cardiomyopathy Earlier, Enhancing Clinical Care Viz.ai, a leading company in AI-powered disease detection and intelligent care coordination, has announced compelling new clinical data demonstrating the…
Coya Therapeutics Advances Treg-Derived Exosome Program Coya Therapeutics, Inc. (“Coya” or the “Company”), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function, has provided…
Global Pharma Leader Adopts ValGenesis iClean for Digital Cleaning Validation ValGenesis, Inc., a global leader in digital validation lifecycle management solutions, has announced a significant milestone in its collaboration with…
Epicrispr Biotech Raises $68M for FSHD Epigenetic Therapy Trial Epicrispr Biotechnologies, a pioneering biotechnology company dedicated to developing curative therapies, has announced the successful first close of its Series B…
RenovoRx TAMP™ Pre-Clinical Results to Be Awarded at SIR 2025 RenovoRx, Inc. (“RenovoRx” or the “Company”), a pioneering life sciences company dedicated to advancing targeted oncology therapies, is pleased to…
Merck Licenses HRS-5346 for Cardiovascular Disease from Hengrui Merck, known as MSD outside of the United States and Canada, and Jiangsu Hengrui Pharmaceuticals Co., Ltd. (“Hengrui Pharma”), a leading global…
Xcell Biosciences Partners with Planet Innovation and Royal Perth Hospital to Advance Cell Therapy Manufacturing Xcell Biosciences Australia Pty Ltd (Xcellbio), a subsidiary of the San Francisco-based biotechnology company specializing…